Achieve Life Sciences, Inc.
ACHV
$2.23
$0.052.29%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 42.11% | 19.44% | 5.12% | 5.92% | 6.66% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 43.37% | -7.30% | -36.24% | -41.51% | -33.21% |
Operating Income | -43.37% | 7.30% | 36.24% | 41.51% | 33.21% |
Income Before Tax | -33.58% | 7.39% | 33.70% | 37.59% | 29.60% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -33.58% | 7.39% | 33.70% | 37.59% | 29.60% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -33.58% | 7.39% | 33.70% | 37.59% | 29.60% |
EBIT | -43.37% | 7.30% | 36.24% | 41.51% | 33.21% |
EBITDA | -43.73% | 7.32% | 36.45% | 41.73% | 33.38% |
EPS Basic | 19.70% | 46.26% | 64.64% | 65.82% | 62.37% |
Normalized Basic EPS | 20.16% | 48.11% | 65.55% | 66.54% | 62.98% |
EPS Diluted | 19.70% | 46.31% | 64.65% | 65.84% | 62.39% |
Normalized Diluted EPS | 20.16% | 48.11% | 65.55% | 66.54% | 62.98% |
Average Basic Shares Outstanding | 61.79% | 60.39% | 68.88% | 70.07% | 87.21% |
Average Diluted Shares Outstanding | 61.79% | 60.39% | 68.88% | 70.07% | 87.21% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |